Navigation Links
Spectral announces second quarter 2009 results
Date:8/13/2009

43 12 Stock-based compensation expense - 22 - 43 Interest on convertible notes payable 41 41 82 82 Unrealized loss on short-term investments 91 - 91 - Changes in non-cash working capital 344 - (39) (167) ----------------------- ----------------------- (44) (185) (605) (579) ----------------------- ----------------------- Financing activities Bank indebtedness (385) 195 - 195 ----------------------- ----------------------- Investing activities Purchase of property, plant and equipment (51) (101) (54) (115) Purchase of commercial instruments (3) - (25) (22) Decrease (increase) in short-term investments 1,001 2 964 (101) Decrease in deferred revenue (43) (5) (86) (8) ----------------------- ----------------------- 904 (104) 799 (246) ----------------------- ----------------------- Increase (decrease) in cash and cash equivalents during the period 475 (94) 194 (630) ----------------------- ----------------------- Cash and cash equivalents - Beginning of period 16 102 297 638 ----------------------- ----------------------- Cash and cash equivalents -
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Eli Lilly and Company (NYSE: LLY ) ... therapies, reflecting Lilly,s diverse oncology pipeline, during the American ... April 18-22 in Philadelphia , Pa.  ... the theme of this year,s AACR meeting and one ... portfolio of therapies that accelerate the pace and progress ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/18/2015)... 18, 2015 Aurigene and ... will be presenting data at the poster sessions ... Cancer Research Annual Meeting (April 18-22 in ... (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene ... (NAMPT) small molecule inhibitors program, which is currently ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
Breaking Biology Technology:Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... SANTA ANA, Calif. , July 21 Irvine Scientific announced ... in women,s health, located in Neuilly en Thelle, France. Effective ... embryo transfer catheters, oocyte retrieval needles, and intra-uterine insemination cannulas ... Prodimed has a long history of developing superior products ...
... Mich., July 21 Neogen Corporation (Nasdaq: NEOG ) ... year, which ended May 31, and a continuation of the company,s ... Neogen,s revenues for FY 2009 were $118,721,000, up from $102,418,000 ... in currency exchange rates that had an unfavorable impact of $2.7 ...
... JERUSALEM, Israel, July 21 Oramed,Pharmaceuticals, ... alternative drug delivery systems, today reported positive results from ... on type 1 diabetic,patients. The completion of this study ... Diabetes Mellitus, whereas, all Oramed,s trials up to,date have ...
Cached Biology Technology:Neogen Reports 16% Increase in Revenues 2Neogen Reports 16% Increase in Revenues 3Neogen Reports 16% Increase in Revenues 4Neogen Reports 16% Increase in Revenues 5Neogen Reports 16% Increase in Revenues 6Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients 2
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... Health conducted a historical analysis to examine the relationship ... HIV prevention budget and HIV incidence in the U.S. ... the January 2007 edition of the American Journal of ... beginning of the epidemic until 1985 (when new infections ...
... medical practice that an antiretroviral drug widely used to treat ... own in patients co-infected with HIV. Their findings demonstrate ... drugs used to treat the AIDS virus. , "Our results ... has been shown to be active against HIV - it ...
... variable amounts in the natural environment in the UK. Dr ... of a pilot study assessing the use of upland sheep ... metals in the Lake District and Wales at the Society ... April). , Significant correlations were found between the amount ...
Cached Biology News:Investment level in HIV prevention programs related to HIV incidence in the United States 2Widely used hepatitis B drug spurs HIV drug resistance 2Widely used hepatitis B drug spurs HIV drug resistance 3Monitoring poisons in the environment -- a woolly matter 2
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
Biology Products: